NASDAQ
33.67USD
+0.60 (+1.81%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.8B
P/E
—
EPS
—
Beta
0.35
52W range
6.92-43.73
Day range
32.95–34.00
Open
33.51
Prev close
33.07
Volume
2.1M
Avg volume
2.1M
Dividend
0.00
IPO
2018-03-29
https://seekingalpha.com/article/4914866-cogent-biosciences-stock-pre-commercial-biotech-with-commercial-stage-leverage · 6/14/2026+0.90
https://www.fool.com/coverage/filings/2026/03/21/high-flying-biotech-stock-up-360-faces-usd48-million-trim-but-remains-this-fund-s-largest-holding/ · 3/21/2026+0.60
https://www.globenewswire.com/news-release/2026/02/28/3246892/0/en/Cogent-Biosciences-Highlights-Additional-Data-with-Six-Bezuclastinib-Posters-from-SUMMIT-Trial-at-2026-AAAAI-Annual-Meeting.html · 2/28/2026+0.80
https://www.fool.com/coverage/filings/2026/02/17/cogent-biosciences-stock-soars-346-in-a-year-but-one-fund-just-sold-off-usd4-5-million/ · 2/17/2026+0.60
https://www.benzinga.com/news/fda/26/01/50129335/cogents-new-stomach-cancer-treatment-cuts-progression-risk-in-half-gets-breakthrough-therapy-tag · 1/26/2026+1.00
https://www.globenewswire.com/news-release/2025/12/06/3201063/0/en/Cogent-Biosciences-Presents-Full-SUMMIT-Results-of-Bezuclastinib-in-Patients-with-NonAdvanced-Systemic-Mastocytosis-NonAdvSM-at-the-67th-Annual-Meeting-of-the-American-Society-of-H.html · 12/6/2025+1.00
https://www.globenewswire.com/news-release/2025/11/12/3185880/0/en/Cogent-Biosciences-Announces-Pricing-of-Concurrent-Public-Offerings-of-Common-Stock-and-1-625-Convertible-Senior-Notes-Due-2031.html · 11/12/2025+0.30
https://www.globenewswire.com/news-release/2025/11/03/3179389/0/en/Cogent-Biosciences-Reports-Recent-Business-Highlights-and-Third-Quarter-2025-Financial-Results.html · 11/3/2025+0.80
https://www.globenewswire.com/news-release/2025/10/24/3172997/0/en/Cogent-Biosciences-Announces-KRAS-Poster-Presentation-at-the-2025-AACR-NCI-EORTC-International-Conference-on-Molecular-Targets-and-Cancer-Therapeutics.html · 10/24/2025+0.80
https://seekingalpha.com/article/4800236-cogent-positive-data-in-nonadvsm-bodes-well-for-2nd-half-advsm-treatment-results · 7/9/2025+1.00
https://www.globenewswire.com/news-release/2025/07/09/3112280/0/en/Cogent-Biosciences-Announces-Pricing-of-Upsized-Public-Offering-of-Shares-of-Common-Stock.html · 7/9/2025+0.50
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
